Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ALOX5 encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid.
Showing 10 out of 205 products:
Human Polyclonal ALOX5 Primary Antibody for ICC, IF - ABIN4276911
Ohkubo, Ito, Minamino, Mishima, Hirata, Hosono, Shibuya, Yokomizo, Shimizu, Watanabe, Majima: Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2013
Show all 2 Pubmed References
Human Polyclonal ALOX5 Primary Antibody for IF (p), IHC (p) - ABIN669651
Wang, Wang, Gao, Qu: The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice. in Drug discoveries & therapeutics 2014
Show all 2 Pubmed References
Human Polyclonal ALOX5 Primary Antibody for ELISA, WB - ABIN251668
Kalayci, Birben, Sackesen, Keskin, Tahan, Wechsler, Civelek, Soyer, Adalioglu, Tuncer, Israel, Lilly: ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. in Allergy 2005
Human Polyclonal ALOX5 Primary Antibody for IHC, ELISA - ABIN1532500
Mancini, Ortiz, Croxatto, Gallo: Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet. in BMC ophthalmology 2013
Human Polyclonal ALOX5 Primary Antibody for ICC, IF - ABIN258593
Lin, Lin, Wu, Chiu, Tang, Hour, Liou, Tu, Yang, Fu: 5-Lipoxygenase inhibitors attenuate TNF-α-induced inflammation in human synovial fibroblasts. in PLoS ONE 2014
The knockdown of arachidonate 5-lipoxygenase (Alox5) gene can induce the decreased levels of bcl/abl (show ABL1 Antibodies) mRNA and BCR/ABL (show ABL1 Antibodies) fusion protein in the K562/ADM (show ADM Antibodies) cells and increased apoptosis rate.
Data suggest that the co-carcinogens benzidine and hydrogen peroxide induce expression of ALOX5 mRNA and protein in tracheobronchial epithelial cells; the co-carcinogens decrease cell proliferation but enhance apoptosis, actions inhibited by knockdown of ALOX5 by RNA interference. Benzidine appears to undergo metabolic activation to benzidine diimine by ALOX5.
This study revealed that epistatic interaction among the ALOX5, ALOX5AP (show ALOX5AP Antibodies) and MPO (show MPO Antibodies) genes played a significant role in vulnerability to ischemic stroke.
The anticancer effects by 13'-COOHs appeared to be partially independent of inhibition of COX-2/5-LOX. Using liquid chromatography tandem mass spectrometry, we found that 13'-COOHs increased intracellular dihydrosphingosine and dihydroceramides after short-time incubation in HCT-116 cells, and enhanced ceramides while decreased sphingomyelins during prolonged treatment
ROS (show ROS1 Antibodies) production induced by the 5-LO pathway mediates the anti-cancer effects of docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine on head and neck squamous cell carcinoma cells.
Specific inhibitors of COX-2 (show COX2 Antibodies) and 5-LOX decreased formation of HKD2 and HKE2 (show PFDN6 Antibodies) Platelets did not form HKs from exogenous 5S-hydroxyeicosatetraenoic acid, implying that COX-1 (show COX1 Antibodies) is not involved
The observation that the coexpression of FLAP (show ALOX5AP Antibodies) with a subset of the 5-LOX mutants restores 5-LOX-wild-type (wt)-like levels of products formed in intact cells suggests a physical protein-protein interaction, beyond colocalization, of 5-LOX and FLAP (show ALOX5AP Antibodies).
Polymorphisms in the 5-Lipoxygenase is associated with Incident Myocardial Infarction.
our results define Alox5 as a key genetic effector of JAK2V617F in driving polycythemia vera (show IGF2BP3 Antibodies)
Adipose tissue eicosapentaenoic acid and arachidonic acid and the ALOX-5 tandem repeat polymorphism did not significantly interact to affect the risk of myocardial infarction.
Results indicate 15-lipoxygenase modified LDL as a new inducer for LOX-1 (show OLR1 Antibodies) expression and as a new ligand for LOX-1 (show OLR1 Antibodies).
Our data showed that besides the high parasite burden and lack of microbicidal molecules, an imbalance with high COX-2 (show COX2 Antibodies) and 5-LOX eicosanoid expression and a lack of regulatory PPAR-gamma (show PPARG Antibodies) cytoplasm-to-nucleus translocation in macrophages were observed in mice that develop cerebral malaria.
Data indicate that 5-lipoxygenase (5-LO)/leukotriene B4 (LTB4 (show PTGR1 Antibodies)) axis orchestrates graft-versus-host disease (GVHD) development and suggest it could be a target for the development of therapeutic strategies for GVHD treatment.
Findings demonstrate that the up-regulation of the ALOX5 gene pathway is responsible for the development of the biochemical and behavioral sequelae of high Hcy brain levels in the context of a neurodegenerative phenotype.
This study demonstrates that LTB4 (show PTGR1 Antibodies) promotes macrophage phagocytosis of bacteria via BLT1, and that BLT2 (show LTB4R2 Antibodies) can fulfill this role in the absence of BL
Homocysteine directly influences 5LO expression levels and establish a previously unknown cross talk between these two pathways.
Dimethyl ester of bilirubin exhibits anti-inflammatory activity through inhibition of secretory phospholipase A2 (show YWHAZ Antibodies), lipoxygenase and cyclooxygenase.
Data suggest that miR (show MLXIP Antibodies)-674-5p (microRNA-674-5p) serves as a negative regulator in 5-LO (arachidonate 5-lipoxygenase) mediated autoimmune liver injury; miR (show MLXIP Antibodies)-674-5p represses expression of 5-LO in hepatocytes in the presence of IL-6 (interleukin-6 (show IL6 Antibodies)) or TNFa (tumor necrosis factor-alpha (show TNF Antibodies)).
Results establish a key role of 5-Lipoxygenase in the development of the tau pathology phenotype and demonstrate it to be a novel viable therapeutic target for the pharmacologic treatment of human tauopathy.
GSAP (show PION Antibodies) cleavage via caspase-3 (show CASP3 Antibodies) is regulated and depend upon the availability of 5-Lipoxygenase in Alzheimer's disease.
[5-lipoxygenase; 5-lox] protein expression and enzyme activity of 5-LOX were significantly higher in horses harbouring encysted larvae in comparison with horses free of encysted larvae
Increased PGE2 production led to reduction in 5-LO products in LPS (show IRF6 Antibodies)-treated equine whole blood via IL-1b (show IL1B Antibodies).
This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid. The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetrenoic acid (leukotriene A4). Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
, arachidonic 5-lipoxygenase alpha-10 isoform
, arachidonic 5-lipoxygenase delta-10-13 isoform
, arachidonic 5-lipoxygenase delta-13 isoform
, arachidonic 5-lipoxygenase delta-p10 isoform
, arachidonic acid 5-lipoxygenase
, leukotriene A4 synthase
, erythroid cell-specific 15-lipoxygenase
, omega-6 lipoxygenase
, 5 - Lipoxygenase
, arachidonate 5-lipoxygenase
, Arachidonate 5-lipoxygenase